$5.21
-0.02-0.38%
At close: Jul 22, 4:05 PM EDT
$5.19
-0.02-0.38%
After Hours: 4:05 PM EDT
15 minutes delayed
Comments
Loading...
Editas Medicine
EDITNASDAQ
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Editas Medicine (NASDAQ:EDIT) Stock, Analyst Ratings, Price Targets, Forecasts
Editas Medicine Inc has a consensus price target of $14.6 based on the ratings of 21 analysts. The high is $36 issued by Wells Fargo on January 4, 2023. The low is $7 issued by Evercore ISI Group on May 30, 2024. The 3 most-recent analyst ratings were released by Oppenheimer, Evercore ISI Group, and Citigroup on June 18, 2024, May 30, 2024, and May 9, 2024, respectively. With an average price target of $11.33 between Oppenheimer, Evercore ISI Group, and Citigroup, there's an implied 118.37% upside for Editas Medicine Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Oppenheimer
Evercore ISI Group
Citigroup
Morgan Stanley
Barclays
1calculated from analyst ratings
Analyst Ratings for Editas Medicine
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/18/2024 | Buy Now | 131.21% | Oppenheimer | Jay Olson | $12 → $12 | Maintains | Perform | Get Alert |
| 05/30/2024 | Buy Now | 34.87% | Evercore ISI Group | Liisa Bayko | $15 → $7 | Maintains | In-Line | Get Alert |
| 05/09/2024 | Buy Now | 189.02% | Citigroup | Samantha Semenkow | $16 → $15 | Maintains | Buy | Get Alert |
| 05/09/2024 | Buy Now | 34.87% | Morgan Stanley | Matthew Harrison | → $7 | Upgrade | Underweight → Equal-Weight | Get Alert |
| 05/09/2024 | Buy Now | 73.41% | Barclays | Gena Wang | $11 → $9 | Maintains | Equal-Weight | Get Alert |
| 02/29/2024 | Buy Now | 208.29% | Citigroup | Samantha Semenkow | $11 → $16 | Maintains | Buy | Get Alert |
| 02/29/2024 | Buy Now | 111.95% | Barclays | Gena Wang | $10 → $11 | Maintains | Equal-Weight | Get Alert |
| 02/27/2024 | Buy Now | 73.41% | JP Morgan | Brian Cheng | $8 → $9 | Maintains | Neutral | Get Alert |
| 12/12/2023 | Buy Now | 285.36% | Truist Securities | Joon Lee | $15 → $20 | Maintains | Buy | Get Alert |
| 10/24/2023 | Buy Now | 111.95% | Citigroup | Samantha Semenkow | → $11 | Upgrade | Neutral → Buy | Get Alert |
| 10/18/2023 | Buy Now | 54.14% | JP Morgan | Brian Cheng | → $8 | Upgrade | Underweight → Neutral | Get Alert |
| 10/17/2023 | Buy Now | — | Cantor Fitzgerald | Eric Schmidt | — | Downgrade | Overweight → Neutral | Get Alert |
| 09/29/2023 | Buy Now | 227.55% | Stifel | Dae Gon Ha | $9 → $17 | Upgrade | Hold → Buy | Get Alert |
| 09/13/2023 | Buy Now | 169.75% | Cantor Fitzgerald | Rick Bienkowski | → $14 | Reiterates | Overweight → Overweight | Get Alert |
| 08/29/2023 | Buy Now | 169.75% | Cantor Fitzgerald | Rick Bienkowski | → $14 | Reiterates | Overweight → Overweight | Get Alert |
| 08/03/2023 | Buy Now | 131.21% | Oppenheimer | Jay Olson | → $12 | Reiterates | Perform → Perform | Get Alert |
| 08/03/2023 | Buy Now | 266.09% | Chardan Capital | Geulah Livshits | $22 → $19 | Maintains | Buy | Get Alert |
| 06/13/2023 | Buy Now | 189.02% | Cantor Fitzgerald | Rick Bienkowski | → $15 | Reiterates | Overweight → Overweight | Get Alert |
| 06/13/2023 | Buy Now | 227.55% | Raymond James | Steven Seedhouse | → $17 | Upgrade | Market Perform → Outperform | Get Alert |
| 05/09/2023 | Buy Now | 131.21% | Oppenheimer | Jay Olson | → $12 | Reiterates | → Perform | Get Alert |
| 05/08/2023 | Buy Now | 54.14% | RBC Capital | Luca Issi | $7 → $8 | Maintains | Sector Perform | Get Alert |
| 05/08/2023 | Buy Now | 169.75% | Credit Suisse | Richard Law | $15 → $14 | Maintains | Neutral | Get Alert |
| 05/08/2023 | Buy Now | 323.89% | Chardan Capital | Geulah Livshits | → $22 | Reiterates | → Buy | Get Alert |
| 02/23/2023 | Buy Now | 189.02% | Credit Suisse | Richard Law | $13 → $15 | Maintains | Neutral | Get Alert |
| 02/23/2023 | Buy Now | 323.89% | Chardan Capital | Geulah Livshits | $35 → $22 | Maintains | Buy | Get Alert |
| 02/23/2023 | Buy Now | 92.68% | RBC Capital | Luca Issi | $14 → $10 | Maintains | Sector Perform | Get Alert |
| 02/01/2023 | Buy Now | 189.02% | Cantor Fitzgerald | Rick Bienkowski | → $15 | Initiates | → Overweight | Get Alert |
| 01/24/2023 | Buy Now | 34.87% | Morgan Stanley | Matthew Harrison | $8 → $7 | Maintains | Underweight | Get Alert |
| 01/23/2023 | Buy Now | 34.87% | SVB Leerink | Mani Foroohar | $6 → $7 | Maintains | Market Perform | Get Alert |
| 01/10/2023 | Buy Now | 15.61% | SVB Leerink | Mani Foroohar | $7 → $6 | Maintains | Market Perform | Get Alert |
| 01/04/2023 | Buy Now | 593.64% | Wells Fargo | Yanan Zhu | $50 → $36 | Maintains | Overweight | Get Alert |
| 12/13/2022 | Buy Now | 111.95% | Citigroup | Samantha Semenkow | → $11 | Initiates | → Neutral | Get Alert |
| 12/06/2022 | Buy Now | 150.48% | Credit Suisse | Richard Law | → $13 | Assumes | → Neutral | Get Alert |
| 11/18/2022 | Buy Now | 189.02% | B of A Securities | Greg Harrison | $18 → $15 | Maintains | Neutral | Get Alert |
| 11/18/2022 | Buy Now | 574.37% | Truist Securities | Joon Lee | $80 → $35 | Maintains | Buy | Get Alert |
| 11/18/2022 | Buy Now | 246.82% | Baird | Joel Beatty | $25 → $18 | Maintains | Outperform | Get Alert |
| 11/18/2022 | Buy Now | 54.14% | Morgan Stanley | Matthew Harrison | $10 → $8 | Maintains | Underweight | Get Alert |
| 11/18/2022 | Buy Now | 169.75% | RBC Capital | Luca Issi | $32 → $14 | Maintains | Sector Perform | Get Alert |
| 11/18/2022 | Buy Now | 131.21% | Oppenheimer | Jay Olson | $28 → $12 | Downgrade | Outperform → Perform | Get Alert |
| 11/18/2022 | Buy Now | 150.48% | Credit Suisse | Tiago Fauth | $25 → $13 | Downgrade | Outperform → Neutral | Get Alert |
| 11/18/2022 | Buy Now | 574.37% | Chardan Capital | Geulah Livshits | $43 → $35 | Maintains | Buy | Get Alert |
| 11/17/2022 | Buy Now | 34.87% | SVB Leerink | Mani Foroohar | $14 → $7 | Maintains | Market Perform | Get Alert |
| 11/08/2022 | Buy Now | 92.68% | Morgan Stanley | Matthew Harrison | $15 → $10 | Maintains | Underweight | Get Alert |
| 11/03/2022 | Buy Now | 516.57% | RBC Capital | Luca Issi | $40 → $32 | Maintains | Sector Perform | Get Alert |
| 11/03/2022 | Buy Now | 381.7% | Baird | Joel Beatty | $30 → $25 | Maintains | Outperform | Get Alert |
| 11/03/2022 | Buy Now | 728.52% | Chardan Capital | Geulah Livshits | $60 → $43 | Maintains | Buy | Get Alert |
| 11/03/2022 | Buy Now | 131.21% | SVB Leerink | Mani Foroohar | $14 → $12 | Maintains | Market Perform | Get Alert |
| 09/29/2022 | Buy Now | 246.82% | B of A Securities | Greg Harrison | → $18 | Initiates | → Neutral | Get Alert |
| 08/04/2022 | Buy Now | 227.55% | Barclays | Gena Wang | $16 → $17 | Maintains | Equal-Weight | Get Alert |
| 05/24/2022 | Buy Now | 54.14% | Goldman Sachs | Madhu Kumar | $10 → $8 | Maintains | Sell | Get Alert |
| 05/09/2022 | Buy Now | 189.02% | Morgan Stanley | Matthew Harrison | $17 → $15 | Maintains | Underweight | Get Alert |
| 04/12/2022 | Buy Now | 227.55% | Morgan Stanley | Matthew Harrison | $16 → $17 | Maintains | Underweight | Get Alert |
| 02/25/2022 | Buy Now | 959.73% | Oppenheimer | Jay Olson | $80 → $55 | Maintains | Outperform | Get Alert |
| 02/25/2022 | Buy Now | 1056.07% | Chardan Capital | Geulah Livshits | $75 → $60 | Maintains | Buy | Get Alert |
| 02/25/2022 | Buy Now | 420.23% | SVB Leerink | Rick Bienkowski | $41 → $27 | Maintains | Market Perform | Get Alert |
| 01/06/2022 | Buy Now | 362.43% | Morgan Stanley | Matthew Harrison | $37 → $24 | Maintains | Underweight | Get Alert |
| 10/19/2021 | Buy Now | 689.98% | SVB Leerink | Rick Bienkowski | — | Initiates | → Market Perform | Get Alert |
| 09/24/2021 | Buy Now | 1152.41% | Stifel | Dae Gon Ha | — | Initiates | → Hold | Get Alert |
| 09/10/2021 | Buy Now | 1441.43% | Oppenheimer | Jay Olson | — | Upgrade | Perform → Outperform | Get Alert |
| 08/09/2021 | Buy Now | 1441.43% | Truist Securities | Joon Lee | — | Upgrade | Hold → Buy | Get Alert |
| 08/05/2021 | Buy Now | 1056.07% | Evercore ISI Group | Liisa Bayko | — | Upgrade | Underperform → Outperform | Get Alert |
FAQ
What is the target price for Editas Medicine (EDIT) stock?
The latest price target for Editas Medicine (NASDAQ:EDIT) was reported by Oppenheimer on June 18, 2024. The analyst firm set a price target for $12.00 expecting EDIT to rise to within 12 months (a possible 131.21% upside). 17 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Editas Medicine (EDIT)?
The latest analyst rating for Editas Medicine (NASDAQ:EDIT) was provided by Oppenheimer, and Editas Medicine maintained their perform rating.
When was the last upgrade for Editas Medicine (EDIT)?
The last upgrade for Editas Medicine Inc happened on May 9, 2024 when Morgan Stanley raised their price target to $7. Morgan Stanley previously had an underweight for Editas Medicine Inc.
When was the last downgrade for Editas Medicine (EDIT)?
The last downgrade for Editas Medicine Inc happened on October 17, 2023 when Cantor Fitzgerald changed their price target from N/A to N/A for Editas Medicine Inc.
When is the next analyst rating going to be posted or updated for Editas Medicine (EDIT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Editas Medicine, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Editas Medicine was filed on June 18, 2024 so you should expect the next rating to be made available sometime around June 18, 2025.
Is the Analyst Rating Editas Medicine (EDIT) correct?
While ratings are subjective and will change, the latest Editas Medicine (EDIT) rating was a maintained with a price target of $12.00 to $12.00. The current price Editas Medicine (EDIT) is trading at is $5.19, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.